Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study

Department of Anesthesiology and Intensive Care Medicine, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.
Anesthesia and analgesia (Impact Factor: 3.42). 12/2008; 107(6):1798-806. DOI: 10.1213/ane.0b013e31818524c1
Source: PubMed

ABSTRACT We determined whether whole blood impedance aggregometry using the Multiplate detects the effects of antiplatelet drugs as reliably as does classical light transmission aggregometry (LTA) or the platelet function analyzer PFA-100(R).
Multiplate (M) assays, measuring changes in electrical resistance as aggregation units over time (AU*min), and LTA assays induced by collagen (COL), adenosine diphosphate (ADP) or arachidonic acid (AA) and PFA-100 testing, using epinephrine (PFA100-EPI) or ADP (PFA100-ADP) cartridges, were performed simultaneously using arterial blood samples obtained before induction of anesthesia in 70 consecutive patients scheduled for elective coronary artery bypass grafting. Patients in group A (n = 48) served as controls, patients in group B (n = 11) received aspirin 100 mg/d and those in group C (n = 11) aspirin 100 mg/d and clopidogrel 75 mg/d until the day before surgery.
In controls the median (1st, 3rd quartiles) change in impedance AU*min for M-COL (374 [231-469]) was significantly greater than in patients receiving aspirin (164 [86-211], P = 0.0009) or receiving aspirin and clopidogrel (118 [101-244], P = 0.004). M-ADP values in controls were 258 (158-389), in patients receiving aspirin 261 (159-393), and in patients receiving aspirin and clopidogrel 88 (48-231, P = 0.054). M-AA values were significantly lower in patients receiving aspirin alone (45 [28-60], P = 0.0004) or aspirin and clopidogrel (44 [26-221], P = 0.008) than in controls (200 [86-345]). The areas under the receiver operating characteristic curves indicating the ability to discriminate patients taking aspirin from those not taking aspirin were comparable for COL and AA assays using whole blood impedance aggregometry or classical LTA (M-COL 0.84 [P = 0.001], LTA-COL 0.85 [P = < .001], M-AA 0.84 [P = < .001] and LTA-AA 0.87 [P = < .001]), but only 0.74 for PFA-100-EPI (P = 0.03). Similarly, for discrimination of patients not taking antiplatelet drugs from patients taking clopidogrel and aspirin the areas under the receiver operating characteristic curve were also comparable for both aggregometry methods M-COL 0.77 (P = 0.006), LTA-COL 0.78 (P = 0.004), M-ADP 0.74 (P = 0.015), LTA-ADP 0.73 (P = 0.018).
Results achieved with the bedside Multiplate assays were not different than those obtained with classical aggregometry for detecting the effects of aspirin and clopidogrel in preoperative patients scheduled for elective cardiac surgery.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Inhibition of components of the complement system or of its receptorshas been postulated as a concept for primary andsecondary prevention in atherosclerosis and was applied in clinical trials. Although the anaphylatoxin-receptors C3aR and C5aR are commonly associated with inflammatory cells, in vitro studies suggested their expression also on platelets.
    Atherosclerosis 12/2014; 238(2). DOI:10.1016/j.atherosclerosis.2014.12.002 · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Platelet responsiveness to aspirin in people with cerebrovascular disease is poorly understood.Objectives To determine: (1) normal reference range, imprecision and reproducibility of the Multiplate instrument in healthy volunteers naive to aspirin, (2) imprecision and reproducibility of the Multiplate instrument in acute stroke and transient ischaemic attack (TIA) (3) the relationship between aspirin responsiveness and clinical outcome.Materials and Methods We evaluated platelet function response to three agonists [Adenosine Diphosphate (ADP), Arachidonic Acid (AA), Collagen (Col)] using the Mulitplate platelet function analyser in a 2 phase pilot study. In phase 1 we recruited healthy volunteers to determine the normal reference range and imprecision of the Multiplate instrument. In phase 2 we assessed platelet function in acute stroke or TIA patients presenting to hospital. These patients were bled within 24 hours of presentation and between 12 – 24 hours after ≥75mg dose of Aspirin. Patients were followed up to 1 year to assess mortality and recurrent cardiovascular event.Results29 healthy volunteers and 81 stroke/TIA patients were recruited. On assessing components of variance, Multiplate testing is reproducible and precise in volunteers and stroke/TIA patients. In stroke patients receiving aspirin, Bland-Altman plots show initial day 1 measurement provided a reliable measure of continuing response to aspirin at day 3. We defined one third of patients as aspirin resistant (31.8% (95% CI: 22.1% to 42.8%)) using cut off mean aggregation of ≥23.08% for AA and mean aggregation of ≥80.76% for ADP.Conclusion The Multiplate device gives reproducible, precise results in volunteers and stroke/TIA patients.This article is protected by copyright. All rights reserved.
    European Journal Of Haematology 06/2014; 94(2). DOI:10.1111/ejh.12406 · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Storage impairs platelet function. It was hypothesized that multiple electrode aggregometry in vitro could be used to follow aggregability in platelet concentrates over time and that the results predict the efficacy of platelet transfusion in an ex vivo transfusion model. In vitro platelet aggregability was assessed in apheresis and pooled buffy coat platelet concentrates (BCs) (n = 13 each) using multiple electrode aggregometry with different agonists 1, 3, 5 and 7 days after preparation. In the ex vivo transfusion model, whole blood samples from nine healthy volunteers were collected every second day. The samples were supplemented with stored platelets (+146 × 10(9) × l(-1)) from the same unit 1, 3, 5 and 7 days after preparation. Platelet aggregability was assessed in the concentrate and in the whole blood samples before and after platelet supplementation. There was a continuous reduction in in vitro platelet aggregability over time in both apheresis and pooled BCs. The same pattern was observed after ex vivo addition of apheresis and pooled BCs to whole blood samples. The best correlation between in vitro aggregability and changes in aggregation after addition was achieved with collagen as agonist (r = 0.67, p < 0.001). In conclusion, multiple electrode aggregometry can be used to follow aggregability in platelet concentrates in vitro, and the results predict with moderate accuracy changes in aggregation after addition of platelet concentrate to whole blood samples.
    Platelets 07/2014; 26(2):1-6. DOI:10.3109/09537104.2014.898141 · 2.63 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014